5 drug(s) with this reaction
5,972 total reports
Therapeutic Product Effect Incomplete has been reported as an adverse reaction across 5 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 5,972 adverse event reports mention therapeutic product effect incomplete in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with therapeutic product effect incomplete, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have therapeutic product effect incomplete listed in their FDA adverse event reports, sorted by report count:
In addition to therapeutic product effect incomplete, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
5 drug(s) manufactured by Amgen Inc have therapeutic product effect incomplete listed in their FDA adverse event reports: Otezla, APREMILAST, ERENUMAB-AOOE, PANITUMUMAB, ROMOSOZUMAB-AQQG.
There are a combined 5,972 reports of therapeutic product effect incomplete across 5 Amgen Inc drug(s) in the FDA adverse event database.